Jean‐Claude Becker

Author

Jean‐Claude Becker

Also Known As

J Becker, J. C. Becker, J. Szechinski, J.-C. Becker, J.‐C. Becker, JEAN-CLAUDE BECKER, Jean-Claude Becker, Jean‐Claude Becker

Publications

5.7K

Citations

H-Index

Concepts

All Affiliations

Bristol-Myers Squibb (Germany)University of Leeds University of Alabama at Birmingham Center for Rheumatology Universitair Ziekenhuis Leuven

About

Jean‐Claude Becker is an author at Bristol-Myers Squibb (Germany) specializing in medicine, radiation oncology, and ophthalmology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	2	2	63
2	Applied Physiology	1	1	36
3	Orthopaedics	1	1	36
4	Surgical Oncology	1	1	27
5	Immunotherapy	1	1	27

Jean‐Claude Becker

Publications

5.6K

Citations

H-Index

Page 1

	Year	Citations
Abatacept for Rheumatoid Arthritis Refractory to Tumor Necrosis Factor α Inhibition Mark C. Genovese, Jean‐Claude Becker, Michael Schiff, New England Journal of Medicine	2005	1.2K
Treatment of Rheumatoid Arthritis by Selective Inhibition of T-Cell Activation with Fusion Protein CTLA4Ig Joel M. Kremer, René Westhovens, Marc Léon, New England Journal of Medicine	2003	1.1K
Effects of Abatacept in Patients with Methotrexate-Resistant Active Rheumatoid Arthritis Joel M. Kremer, Harry K. Genant, Larry W. Moreland, Annals of Internal Medicine	2006	710
Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: Twelve‐month results of a phase iib, double‐blind, randomized, placebo‐controlled trial Joel M. Kremer, Maxime Dougados, Paul Emery, Arthritis & Rheumatism	2005	445
Safety of the selective costimulation modulator abatacept in rheumatoid arthritis patients receiving background biologic and nonbiologic disease‐modifying antirheumatic drugs: A one‐year randomized, placebo‐controlled study Michael E. Weinblatt, Bernard Combe, A. Covucci, Arthritis & Rheumatism	2006	383
Costimulatory blockade in patients with rheumatoid arthritis: A pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion Larry W. Moreland, Rieke Alten, Filip Van den Bosch, Arthritis & Rheumatism	2002	379
The efficacy and safety of abatacept in patients with non–life‐threatening manifestations of systemic lupus erythematosus: Results of a twelve‐month, multicenter, exploratory, phase IIb, randomized, double‐blind, placebo‐controlled trial Joan T. Merrill, Rubén Burgos‐Vargas, René Westhovens, Arthritis & Rheumatism	2010	371
Abatacept in the treatment of patients with psoriatic arthritis: Results of a six‐month, multicenter, randomized, double‐blind, placebo‐controlled, phase II trial Philip J. Mease, Mark C. Genovese, Geoffrey Gladstein, Arthritis & Rheumatism	2010	296
Results of a two‐year followup study of patients with rheumatoid arthritis who received a combination of abatacept and methotrexate Joel M. Kremer, Harry K. Genant, Larry W. Moreland, Arthritis & Rheumatism	2008	173
Long-term safety, efficacy and inhibition of radiographic progression with abatacept treatment in patients with rheumatoid arthritis and an inadequate response to methotrexate: 3-year results from the AIM trial Joel M. Kremer, Anthony S. Russell, Paul Emery, Annals of the Rheumatic Diseases	2011	143

Page 1